Accelerated Phase CML: Outcomes in Newly Diagnosed Vs. Progression From Chronic Phase

Overview

Journal Curr Hematol Malig Rep

Publisher Current Science

Specialties Hematology
Oncology

Date 2016 Mar 3

PMID 26932346

Citations 5

Authors

Sudipto Mukherjee

Matt Kalaycio

Affiliations

Soon will be listed here.

Abstract

The introduction of tyrosine kinase inhibitors (TKIs) has fundamentally changed the management of chronic myeloid leukemia (CML). Disease progression to advanced phase (accelerated or blast phase) has been reduced to 1 to 1.5 % per year from more than 20 % per year in the pre-TKI era. However, once the disease has progressed to accelerated or blast phase, there is no consensus regarding optimal therapy. The prognosis of these patients is dismal with median survival ranging from 7 to 11 months. TKIs along with allogeneic hematopoietic cell transplantation are conventional strategies in managing these patients but there are very few long-term survivors. Advanced phase CML represents the new frontier for CML treatment where research is critically needed to improve patient outcomes.

Citing Articles

In Silico Molecular Modeling of Four New Afatinib Derived Molecules Targeting the Inhibition of the Mutated Form of BCR-ABL T315I.

Rocha K, Nascimento E, de Jesus R, Martins J Molecules. 2024; 29(17).

PMID: 39275102 PMC: 11397288. DOI: 10.3390/molecules29174254.

Prognosis in Chronic Myeloid Leukemia: Baseline Factors, Dynamic Risk Assessment and Novel Insights.

Iezza M, Cortesi S, Ottaviani E, Mancini M, Venturi C, Monaldi C Cells. 2023; 12(13).

PMID: 37443737 PMC: 10341256. DOI: 10.3390/cells12131703.

Magnitude and Temporal Trend of the Chronic Myeloid Leukemia: On the Basis of the Global Burden of Disease Study 2019.

Hu Y, Li Q, Hou M, Peng J, Yang X, Xu S JCO Glob Oncol. 2021; 7:1429-1441.

PMID: 34591599 PMC: 8492379. DOI: 10.1200/GO.21.00194.

Neurokinin-1 receptor is an effective target for treating leukemia by inducing oxidative stress through mitochondrial calcium overload.

Ge C, Huang H, Huang F, Yang T, Zhang T, Wu H Proc Natl Acad Sci U S A. 2019; 116(39):19635-19645.

PMID: 31488714 PMC: 6765257. DOI: 10.1073/pnas.1908998116.

Assessment of the Number and Phenotype of Macrophages in the Human BMB Samples of CML.

Song J, Dian Z, Wen Y, Mei F, Li R, Sa Y Biomed Res Int. 2016; 2016:8086398.

PMID: 27999815 PMC: 5143699. DOI: 10.1155/2016/8086398.

References

Saglio G, Kim D, Issaragrisil S, le Coutre P, Etienne G, Lobo C . Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia. N Engl J Med. 2010; 362(24):2251-9. DOI: 10.1056/NEJMoa0912614. View

Giralt S, Arora M, Goldman J, Lee S, Maziarz R, McCarthy P . Impact of imatinib therapy on the use of allogeneic haematopoietic progenitor cell transplantation for the treatment of chronic myeloid leukaemia. Br J Haematol. 2007; 137(5):461-7. DOI: 10.1111/j.1365-2141.2007.06582.x. View

Gratwohl A, Hermans J, Niederwieser D, Frassoni F, Arcese W, Gahrton G . Bone marrow transplantation for chronic myeloid leukemia: long-term results. Chronic Leukemia Working Party of the European Group for Bone Marrow Transplantation. Bone Marrow Transplant. 1993; 12(5):509-16. View

Silver R, Cortes J, Waltzman R, Mone M, Kantarjian H . Sustained durability of responses and improved progression-free and overall survival with imatinib treatment for accelerated phase and blast crisis chronic myeloid leukemia: long-term follow-up of the STI571 0102 and 0109 trials. Haematologica. 2009; 94(5):743-4. PMC: 2675690. DOI: 10.3324/haematol.2009.006999. View

OBrien S, Berman E, Moore J, Pinilla-Ibarz J, Radich J, Shami P . NCCN Task Force report: tyrosine kinase inhibitor therapy selection in the management of patients with chronic myelogenous leukemia. J Natl Compr Canc Netw. 2011; 9 Suppl 2:S1-25. PMC: 4234100. DOI: 10.6004/jnccn.2011.0125. View

Hochhaus A, La Rosee P . Imatinib therapy in chronic myelogenous leukemia: strategies to avoid and overcome resistance. Leukemia. 2004; 18(8):1321-31. DOI: 10.1038/sj.leu.2403426. View

Gambacorti-Passerini C, Kantarjian H, Kim D, Khoury H, Turkina A, Brummendorf T . Long-term efficacy and safety of bosutinib in patients with advanced leukemia following resistance/intolerance to imatinib and other tyrosine kinase inhibitors. Am J Hematol. 2015; 90(9):755-68. PMC: 5132035. DOI: 10.1002/ajh.24034. View

OBrien S, Berman E, Borghaei H, DeAngelo D, Devetten M, Devine S . NCCN clinical practice guidelines in oncology: chronic myelogenous leukemia. J Natl Compr Canc Netw. 2009; 7(9):984-1023. DOI: 10.6004/jnccn.2009.0065. View

Cortes J, Kantarjian H . Advanced-phase chronic myeloid leukemia. Semin Hematol. 2003; 40(1):79-86. DOI: 10.1053/shem.2003.50005. View

10.

McGlave P . Therapy of chronic myelogenous leukemia with related or unrelated donor bone marrow transplantation. Leukemia. 1992; 6 Suppl 4:115-7. View

11.

Jabbour E, Cortes J, Santos F, Jones D, OBrien S, Rondon G . Results of allogeneic hematopoietic stem cell transplantation for chronic myelogenous leukemia patients who failed tyrosine kinase inhibitors after developing BCR-ABL1 kinase domain mutations. Blood. 2010; 117(13):3641-7. PMC: 4186643. DOI: 10.1182/blood-2010-08-302679. View

12.

Cortes J, Kim D, Pinilla-Ibarz J, le Coutre P, Paquette R, Chuah C . A phase 2 trial of ponatinib in Philadelphia chromosome-positive leukemias. N Engl J Med. 2013; 369(19):1783-96. PMC: 3886799. DOI: 10.1056/NEJMoa1306494. View

13.

Oehler V, Gooley T, Snyder D, Johnston L, Lin A, Cummings C . The effects of imatinib mesylate treatment before allogeneic transplantation for chronic myeloid leukemia. Blood. 2006; 109(4):1782-9. PMC: 1794075. DOI: 10.1182/blood-2006-06-031682. View

14.

Breccia M, Palandri F, Iori A, Colaci E, Latagliata R, Castagnetti F . Second-generation tyrosine kinase inhibitors before allogeneic stem cell transplantation in patients with chronic myeloid leukemia resistant to imatinib. Leuk Res. 2009; 34(2):143-7. DOI: 10.1016/j.leukres.2009.04.036. View

15.

Lugo T, Pendergast A, Muller A, Witte O . Tyrosine kinase activity and transformation potency of bcr-abl oncogene products. Science. 1990; 247(4946):1079-82. DOI: 10.1126/science.2408149. View

16.

Ohanian M, Kantarjian H, Quintas-Cardama A, Jabbour E, Abruzzo L, Verstovsek S . Tyrosine kinase inhibitors as initial therapy for patients with chronic myeloid leukemia in accelerated phase. Clin Lymphoma Myeloma Leuk. 2013; 14(2):155-162.e1. PMC: 3959284. DOI: 10.1016/j.clml.2013.08.008. View

17.

Kantarjian H, Keating M, Estey E, OBrien S, Pierce S, Beran M . Treatment of advanced stages of Philadelphia chromosome-positive chronic myelogenous leukemia with interferon-alpha and low-dose cytarabine. J Clin Oncol. 1992; 10(5):772-8. DOI: 10.1200/JCO.1992.10.5.772. View

18.

Palandri F, Castagnetti F, Alimena G, Testoni N, Breccia M, Luatti S . The long-term durability of cytogenetic responses in patients with accelerated phase chronic myeloid leukemia treated with imatinib 600 mg: the GIMEMA CML Working Party experience after a 7-year follow-up. Haematologica. 2009; 94(2):205-12. PMC: 2635408. DOI: 10.3324/haematol.13529. View

19.

Calabretta B, Perrotti D . The biology of CML blast crisis. Blood. 2004; 103(11):4010-22. DOI: 10.1182/blood-2003-12-4111. View

20.

Giles F, Cortes J, Baker S, Thomas D, OBrien S, Smith T . Troxacitabine, a novel dioxolane nucleoside analog, has activity in patients with advanced leukemia. J Clin Oncol. 2001; 19(3):762-71. DOI: 10.1200/JCO.2001.19.3.762. View